Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:CVSI OTCMKTS:GSAC NASDAQ:KTTA NYSE:NKGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVSICV Sciences$0.03+5.5%$0.04$0.02▼$0.05$6.08M0.6592,741 shs125,124 shsGSACGelStat$0.00$0.00$0.00▼$0.00$1.50M3.221.22 million shs3.34 million shsKTTAPasithea Therapeutics$0.77-2.3%$0.73$0.65▼$7.50$5.87M0.28181,227 shs52,556 shsNKGNNKGen Biotech$0.13-7.0%$0.18$0.10▼$0.96$5.96M1.191.49 million shs130 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVSICV Sciences-1.20%-0.30%-14.32%+11.53%-27.69%GSACGelStat0.00%0.00%0.00%0.00%+33.33%KTTAPasithea Therapeutics+0.86%-0.88%+12.71%+0.38%-79.56%NKGNNKGen Biotech-7.02%0.00%-5.36%-59.85%-83.01%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVSICV Sciences$0.03+5.5%$0.04$0.02▼$0.05$6.08M0.6592,741 shs125,124 shsGSACGelStat$0.00$0.00$0.00▼$0.00$1.50M3.221.22 million shs3.34 million shsKTTAPasithea Therapeutics$0.77-2.3%$0.73$0.65▼$7.50$5.87M0.28181,227 shs52,556 shsNKGNNKGen Biotech$0.13-7.0%$0.18$0.10▼$0.96$5.96M1.191.49 million shs130 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVSICV Sciences-1.20%-0.30%-14.32%+11.53%-27.69%GSACGelStat0.00%0.00%0.00%0.00%+33.33%KTTAPasithea Therapeutics+0.86%-0.88%+12.71%+0.38%-79.56%NKGNNKGen Biotech-7.02%0.00%-5.36%-59.85%-83.01%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCVSICV Sciences 0.00N/AN/AN/AGSACGelStat 0.00N/AN/AN/AKTTAPasithea Therapeutics 0.00N/AN/AN/ANKGNNKGen Biotech 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCVSICV Sciences$15.70M0.41N/AN/A$0.01 per share3.47GSACGelStatN/AN/AN/AN/AN/AN/AKTTAPasithea TherapeuticsN/AN/AN/AN/A$10.60 per shareN/ANKGNNKGen BiotechN/AN/AN/AN/A($2.68) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCVSICV Sciences-$2.39MN/A0.00∞N/A-10.36%-80.82%-19.38%N/AGSACGelStatN/AN/A0.00∞N/AN/AN/AN/AN/AKTTAPasithea Therapeutics-$13.90M-$7.550.00∞N/AN/A-88.60%-81.10%11/11/2025 (Estimated)NKGNNKGen Biotech-$82.94M-$2.45N/A∞N/AN/AN/A-479.36%N/ALatest GSAC, NKGN, CVSI, and KTTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025KTTAPasithea TherapeuticsN/A-$0.66N/A-$0.66N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCVSICV SciencesN/AN/AN/AN/AN/AGSACGelStatN/AN/AN/AN/AN/AKTTAPasithea TherapeuticsN/AN/AN/AN/AN/ANKGNNKGen BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCVSICV Sciences0.121.040.30GSACGelStatN/AN/AN/AKTTAPasithea TherapeuticsN/A4.974.97NKGNNKGen BiotechN/A0.020.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCVSICV SciencesN/AGSACGelStatN/AKTTAPasithea Therapeutics23.92%NKGNNKGen Biotech76.17%Insider OwnershipCompanyInsider OwnershipCVSICV Sciences3.80%GSACGelStat20.50%KTTAPasithea Therapeutics2.70%NKGNNKGen Biotech10.36%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCVSICV Sciences70184.79 million177.77 millionNot OptionableGSACGelStat23.74 billion2.97 billionNot OptionableKTTAPasithea Therapeutics37.44 million7.24 millionNot OptionableNKGNNKGen BiotechN/A44.95 million40.29 millionNot OptionableGSAC, NKGN, CVSI, and KTTA HeadlinesRecent News About These CompaniesFinancial Contrast: NKGen Biotech (NYSE:NKGN) versus Finch Therapeutics Group (NASDAQ:FNCH)September 10 at 2:55 AM | americanbankingnews.comNKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. Acquisition; Gains Full Control of Global Manufacturing and Intellectual Property AssetsSeptember 9 at 8:05 AM | globenewswire.comNKGen Biotech To Present on Allogeneic Enhanced NK Cells without Lymphodepletion in Solid Tumors at the 13th Annual Immuno-Oncology SummitAugust 6, 2025 | globenewswire.comNKGen Biotech Presents Troculeucel Mechanism of Action with Corresponding Phase 1 Biomarker Data at the Alzheimer’s Association International Conference 2025July 29, 2025 | finance.yahoo.comNKGen Biotech Presents Troculeucel Mechanism of Action with Corresponding Phase 1 Biomarker Data at the Alzheimer's Association International Conference 2025July 28, 2025 | globenewswire.comNKGen Biotech to Present at the Alzheimer's Association International Conference 2025July 22, 2025 | globenewswire.comNKGen Receives FDA Expanded Access Protocol Authorization for Landmark Treatment of Several Neurodegenerative DiseasesJuly 21, 2025 | finance.yahoo.comNKGen Biotech and HekaBio Enter Strategic Partnership to Bring Novel NK Cell Therapy to JapanJuly 17, 2025 | globenewswire.comNKGen Biotech, Inc.: NKGen Biotech Announces New Funding to Regain Compliance with Reporting Obligations and Listing StandardsJuly 17, 2025 | finanznachrichten.deNKGen Biotech Announces New Funding to Regain Compliance with Reporting Obligations and Listing StandardsJuly 16, 2025 | globenewswire.comNKGen Biotech Administers First Dose of Troculeucel to Alzheimer’s ...July 12, 2025 | morningstar.comMNKGen Biotech, Inc.: NKGen Biotech Administers First Dose of Troculeucel to Alzheimer's Patient Who Continued to Decline Cognitively While on Prior Amyloid-Targeting TherapyJuly 11, 2025 | finanznachrichten.deNKGen Biotech Administers First Dose of Troculeucel to Alzheimer's Patient Who Continued to Decline Cognitively While on Prior Amyloid-Targeting TherapyJuly 10, 2025 | globenewswire.comNKGen Biotech Announces International and U.S. Expansion of Phase 1/2a Troculeucel Alzheimer's Trial with Activation of Clinical Sites in Canada and FloridaJune 23, 2025 | globenewswire.comNkgen biotech sees $2.5 million stock purchase by major shareholderJune 4, 2025 | investing.comNKGen Biotech Enters Stock Purchase AgreementMay 20, 2025 | tipranks.comNKGen CEO puts skin in the game, investing $2.6M to move biotech toward Alzheimer’s readoutMay 8, 2025 | fiercebiotech.comFNKGen Biotech Chairman & CEO Paul Y. Song, M.D.May 8, 2025 | globenewswire.comNKGen Biotech to Present Troculeucel Clinical and Biomarker Results at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual MeetingMay 7, 2025 | finance.yahoo.comNKGen Biotech To Present on the Use of Troculeucel for Alzheimer's and Parkinson's Disease at the 7th China International Biotechnology Conference & ExhibitionApril 14, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGSAC, NKGN, CVSI, and KTTA Company DescriptionsCV Sciences OTCMKTS:CVSI$0.03 +0.00 (+5.47%) As of 03:54 PM EasternCV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The company offers its products under the PlusCBD, ProCBD, HappyLane, CVAcute, CVDefense, and PlusCBD Pet brands in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, elect distributors, brick and mortar retailers, and select e-tailers. It is also developing cannabinoids intended to treat medical indications, including CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.GelStat OTCMKTS:GSAC$0.0004 0.00 (0.00%) As of 09/11/2025 02:08 PM EasternGelStat Corporation, a consumer health care company, engages in the research, development, and marketing of over-the-counter and other non-prescription consumer health care products. Its products include GelStat Migraine, a patented solution used for pain relief from migraine headaches; Chews 2 Lose, an appetite suppressant gum for diet aide; All Natural Speed, an energy supplement product; and GelStat Sleep, a product for relief from sleep disorders and its associated symptoms. The company sells its products to retailers, wholesalers, specialty distributors, and catalog merchandisers both directly and through external sales brokers. GelStat Corporation was founded in 2002 and is headquartered in Palm City, Florida.Pasithea Therapeutics NASDAQ:KTTA$0.77 -0.02 (-2.31%) Closing price 04:00 PM EasternExtended Trading$0.78 +0.01 (+1.19%) As of 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.NKGen Biotech NYSE:NKGN$0.13 -0.01 (-7.02%) As of 09:43 AM EasternNKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
